arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Pelthos Therapeutics Inc.

PTHS

$28.65 ▼ -0.60 (-2.03%) at close

16 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Pelthos Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $94.9M

Dividend Yield —

Revenue Growth —

Op. Margin -120.0% ↘

ROIC -37.3% ↘

FCF / Share $-4.02

Trailing P/E —

Price / Book 2.8x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

16-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$10.91M

↓ -33.9% —

Net Income Profit after all expenses

$-10.24M

↓ -420.2% —

Operating Margin Operating profit as % of sales

-120.0%

↓ -65.0% 0th

FCF / Share Free cash flow per share

$-4.02

↓ -290.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability

Returns

Financial Health ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Dec 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q2 FY2022 Aug 10, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
EPS Growth YoY (%)	3.7% Caution ↑ Caution Improving Year-over-year change in earnings per share Optimal: > 10%	-156.5% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-82.8% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-73.5% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	41.6% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	87.6% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	79.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	67.4% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	36.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-420.2% Weak ↓ Weak Declining Year-over-year change in net income	-1024.8% Weak ↓ Weak Declining Year-over-year change in net income	23.2% Good ↓ Good Declining Year-over-year change in net income	23.2% Good ↑ Good Improving Year-over-year change in net income	23.2% Good ↑ Good Improving Year-over-year change in net income	52.3% Excellent ↑ Excellent Improving Year-over-year change in net income	-165.1% Weak → Weak Stable Year-over-year change in net income	-165.1% Weak Weak Year-over-year change in net income	-165.1% Weak Weak Year-over-year change in net income	—	—	—	—	—	—	—
FCF Growth YoY (%)	-290.0% Weak Weak Year-over-year change in free cash flow	—	—	—	75.7% Excellent Excellent Year-over-year change in free cash flow	—	—	—	-172.1% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Dec 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q2 FY2022 Aug 10, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Operating Margin (%) (%)	-120.0% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-900%)	-72.7% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-585%)	-207.4% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1483%)	—	—	—	—	—	—	—	—	—	—	—	—	—
Effective Tax Rate (%) (%)	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	24.2% Fair ↑ Fair Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	2.8% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—	—	—	—	—	—
Profit Margin (%) (%)	-93.9% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-882%)	-131.3% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1194%)	-26.6% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-321%)	—	—	—	—	—	—	—	—	—	—	—	—	—
FCF Margin (%) (%)	-122.1% Weak → Weak Stable Free cash flow as a percentage of revenue Optimal: > 10%	-37.9% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-206.0% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—	—	—	—	—	—	—	—
FCF / Net Income (x)	1.30x Good ↓ Good Declining Free cash flow relative to reported net income Optimal: > 1x	0.29x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	7.75x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.23x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.32x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.35x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	0.78x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.09x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.27x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.20x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.18x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Dec 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q2 FY2022 Aug 10, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Return on Invested Capital (%)	-37.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-23.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-25.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	39.3% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	43.7% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	53.1% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	113.4% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	763.5% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-135.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	47.5% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	17.3% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	12.5% Good Good Return earned on debt + equity capital invested Optimal: > 10%	16.3% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—	—	—
Return on Capital (%) (%)	-9.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-9.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-12.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-392.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	—	-133.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-95.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-67.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-48.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-4024.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—	—
Return on Common Equity (%) (%)	-29.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-294%)	-55.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-471%)	-3.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-123%)	30.3% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+102%)	46.9% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+213%)	71.0% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+373%)	179.5% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1097%)	—	-226.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1612%)	62.7% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+318%)	16.4% Good ↓ Good Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+9%)	19.7% Good Good Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+31%)	21.8% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+45%)	—	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Dec 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q2 FY2022 Aug 10, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Interest Coverage (x)	-18.94x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	—	-11.41x Weak Weak Operating income divided by interest expense Optimal: > 5x	-172.29x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	-134.58x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-95.28x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-13.85x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	-6.74x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—
Net Debt (USD)	$-31.98M	$-17.97M	$-14.20M	$-100.00K	$-131.00K	$-513.00K	—	—	$-3.80M	—	—	—	—	$-100.00K	—	—

📊 What does each share earn? 6 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Dec 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q2 FY2022 Aug 10, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Revenue per Share (USD)	$3.29	—	$2.42	—	$0.00	—	—	—	—	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-3.09	$-8.08	$-5.30	$-5.38	$-3.21	$-3.15	$-2.90	$-3.10	$-5.50	$-25.40	$-14.40	$-9.50	$-8.70	—	—	—
Free Cash Flow per Share (USD)	$-4.02	—	$-4.98	$-0.70	$-1.03	—	—	—	$-4.25	—	$-2.61	$-1.93	$-1.56	—	—	—
Book Value per Share (USD)	$10.42	$12.02	$18.85	$-9.65	$-6.85	$-4.45	$-2.45	$-0.31	$1.96	$-16.50	$-59.97	$-48.87	$-39.97	$-31.22	—	—
Tangible Book Value per Share (USD)	$3.09	$4.39	$-1.58	$-9.65	$-6.85	$-4.45	$-2.45	$-0.31	$1.96	$-16.50	$-59.97	$-48.87	$-39.97	$-31.22	—	—
Basic Weighted Avg Shares (shares)	3.31M	—	3.06M	640,518	612,889	—	579,229	577,371	469,099	—	98,452	100,278	111,111	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Dec 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q2 FY2022 Aug 10, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Working Capital (USD)	$44.80M	$27.42M	$24.99M	$-6.49M	—	$-2.71M	$-1.43M	$-182.52K	$1.13M	$-6.44M	—	—	—	$-3.71M	—	—
Total Equity (USD)	$35.10M	$38.88M	$58.25M	$-6.49M	$-4.20M	$-2.71M	$-1.43M	$-182.52K	$1.13M	$-6.44M	$-5.90M	$-4.90M	$-4.44M	$-3.71M	—	$-3.68M

📋 What is driving earnings? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Dec 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q2 FY2022 Aug 10, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Sales/Revenue/Turnover (USD)	$10.91M	$16.50M	$7.41M	—	$0.00	—	—	—	—	—	—	—	—	—	—	—
Depreciation Expense (USD)	$469.00K	—	—	—	$0.00	—	—	—	—	—	—	—	—	—	—	—
Net Income, GAAP (USD)	$-10.24M	$-21.66M	$-1.97M	$-1.97M	$-1.97M	$-1.93M	$-2.56M	$-2.56M	$-2.56M	$-4.04M	$-966.56K	$-966.56K	$-966.56K	—	—	—
Operating Cash Flow (USD)	$-13.13M	$-6.25M	$-15.26M	$-447.27K	$-632.00K	$-670.00K	—	—	$-1.99M	$-356.81K	$-257.24K	$-193.62K	$-173.37K	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 16 quarters

Pelthos Therapeutics Inc.

Analytical Summary

16-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare PTHS with peers